Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 pharmacodynamic study of mycophenolate mofetil (CellCept) in pancreatic cancer
2007-006260-29Phase 4Completed
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate mofetil in pancreatic cancer (PC), sponsored by Fundación de Investigación HM Hospitales. Primary endpoints: Effect of mycophenolate mofetil on VEGF expression in pancreatic tumors and Effect of mycophenolate mofetil on blood vessel expression and cell death. Started Jan 2008; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2007-006260-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006260-29.